UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Editorial: getting bullish about portal hypertension—chronic treatment with oral taurine? Author's reply

Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (4), p.534-535

Ferlitsch, A.

2018

Volltextzugriff (PDF)

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.980-988

2018

Volltextzugriff (PDF)

Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Authors' reply

Alimentary pharmacology & therapeutics, 2018-05, Vol.47 (9), p.1329-1330

2018

Volltextzugriff (PDF)

Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.86-94

2018

Volltextzugriff (PDF)

Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (1), p.139-149

2017

Volltextzugriff (PDF)

Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose‐response study

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (8), p.1162-1169

2018

Volltextzugriff (PDF)

Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis—Authors’ reply

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1537-1538

2018

Volltextzugriff (PDF)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.451-459

2018

Volltextzugriff (PDF)

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

Alimentary pharmacology & therapeutics, 2012-01, Vol.35 (1), p.83-91

2012

Volltextzugriff (PDF)

Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.707-718

2015

Volltextzugriff (PDF)

Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.966-979

2018

Volltextzugriff (PDF)

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

Gut, 2003-06, Vol.52 (6), p.879-885

2003

Volltextzugriff (PDF)

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial

Hepatology (Baltimore, Md.), 2008-05, Vol.47 (5), p.1604-1614

2008

Volltextzugriff (PDF)

Short‐ and long‐term effects of therapy with interferon‐α and pegylated interferon‐α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2005-01, Vol.21 (1), p.49-55

2005

Volltextzugriff (PDF)

Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV―hepatitis C virus coinfected patients

AIDS (London), 2013-01, Vol.27 (2), p.227-232

2013

Volltextzugriff (PDF)

Impact of liver resection on portal venous pressure and renal function

Critical care (London, England), 2013-03, Vol.17 (S2), p.P404-P404, Article P404

2013

Volltextzugriff (PDF)

Letter: sorafenib in portal hypertension - authors' reply

Alimentary pharmacology & therapeutics, 2012-11, Vol.36 (10), p.994-995

2012

Volltextzugriff (PDF)

A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV–HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin

Antiviral therapy, 2012-01, Vol.17 (7), p.1327-1334

2012

Volltextzugriff (PDF)

von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4

Antiviral therapy, 2010-01, Vol.15 (6), p.831-839

2010

Volltextzugriff (PDF)

Short- and long-term effects of therapy with interferon-a and pegylated interferon-α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2005, Vol.21 (1), p.49-55

2005

Volltextzugriff (PDF)

1.P.212 Atorvastatin therapy for treatment of severe hypercholesterolemia in patients undergoing regular LDL-apheresis

Atherosclerosis, 1997-10, Vol.134 (1-2), p.61-61

1997

Volltextzugriff (PDF)

Predictive value of CK-MB test

Circulation (New York, N.Y.), 1981-02, Vol.63 (2), p.467-468

1981

Volltextzugriff (PDF)

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test

PloS one, 2016-02, Vol.11 (2), p.e0149230-e0149230

2016

Volltextzugriff (PDF)

Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis

Hepatology (Baltimore, Md.), 2012-10, Vol.56 (4), p.1439-1447

2012

Volltextzugriff (PDF)

von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma

Gut and Liver, 2020, 14(2), , pp.218-224

2020

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Aktive Filter

SpracheKoreanisch

KollektionEZB Electronic Journals Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(66)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Alimentary Pharmacology & Therapeutics
(18)
Hepatology
(11)
Gut
(6)
Plos One
(6)
Endoscopy International Open
(4)
Antiviral Therapy
(2)
Atherosclerosis
(2)
Aids
(1)
Bmc Gastroenterology
(1)
British Journal Of Cancer
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Editorial: getting bullish about portal hypertension—chronic treatment with oral taurine? Author's reply

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity

Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Authors' reply

Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension

Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease

Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose‐response study

Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis—Authors’ reply

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial

Short‐ and long‐term effects of therapy with interferon‐α and pegylated interferon‐α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C

Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV―hepatitis C virus coinfected patients

Impact of liver resection on portal venous pressure and renal function

Letter: sorafenib in portal hypertension - authors' reply

A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV–HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin

von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4

Short- and long-term effects of therapy with interferon-a and pegylated interferon-α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C

1.P.212 Atorvastatin therapy for treatment of severe hypercholesterolemia in patients undergoing regular LDL-apheresis

Predictive value of CK-MB test

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test

Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis

von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma

Aktive Filter

Suchergebnisse filtern